PT956861E - Terapia combinada compreendendo ribavirina e interferao alfa em doentes sem tratamento antiviral anterior tendo infeccao cronica pelo virus da hepatite c - Google Patents

Terapia combinada compreendendo ribavirina e interferao alfa em doentes sem tratamento antiviral anterior tendo infeccao cronica pelo virus da hepatite c

Info

Publication number
PT956861E
PT956861E PT99303729T PT99303729T PT956861E PT 956861 E PT956861 E PT 956861E PT 99303729 T PT99303729 T PT 99303729T PT 99303729 T PT99303729 T PT 99303729T PT 956861 E PT956861 E PT 956861E
Authority
PT
Portugal
Prior art keywords
ribavirin
hepatitis
virus
patients
combined therapy
Prior art date
Application number
PT99303729T
Other languages
English (en)
Inventor
Janice K Albrecht
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22151354&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT956861(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of PT956861E publication Critical patent/PT956861E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
PT99303729T 1998-05-15 1999-05-13 Terapia combinada compreendendo ribavirina e interferao alfa em doentes sem tratamento antiviral anterior tendo infeccao cronica pelo virus da hepatite c PT956861E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7956698A 1998-05-15 1998-05-15

Publications (1)

Publication Number Publication Date
PT956861E true PT956861E (pt) 2002-08-30

Family

ID=22151354

Family Applications (1)

Application Number Title Priority Date Filing Date
PT99303729T PT956861E (pt) 1998-05-15 1999-05-13 Terapia combinada compreendendo ribavirina e interferao alfa em doentes sem tratamento antiviral anterior tendo infeccao cronica pelo virus da hepatite c

Country Status (23)

Country Link
EP (3) EP0956861B1 (pt)
JP (2) JP5281726B2 (pt)
KR (1) KR100694345B1 (pt)
CN (1) CN1230198C (pt)
AR (1) AR019551A1 (pt)
AT (1) ATE216591T1 (pt)
AU (2) AU766597B2 (pt)
BR (1) BR9910505A (pt)
CA (1) CA2331823A1 (pt)
CZ (1) CZ300540B6 (pt)
DE (1) DE69901321T2 (pt)
DK (1) DK0956861T3 (pt)
ES (1) ES2172288T3 (pt)
HK (1) HK1021131A1 (pt)
HU (1) HU230432B1 (pt)
IL (3) IL139220A0 (pt)
MY (1) MY129244A (pt)
NO (1) NO330715B1 (pt)
NZ (1) NZ507621A (pt)
PT (1) PT956861E (pt)
SK (1) SK288038B6 (pt)
TW (1) TWI277424B (pt)
WO (1) WO1999059621A1 (pt)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003507322A (ja) * 1998-12-18 2003-02-25 シェリング・コーポレーション リバビリン−ＰＥＧ化インターフェロン−α誘発ＨＣＶ併用治療
MXPA02006251A (es) * 1999-12-23 2003-01-28 Ribapharm Inc Composiciones y metodos para l-nucleosidos, l-nucleotidos y sus analogos.
JP4536194B2 (ja) * 2000-02-17 2010-09-01 大日本住友製薬株式会社 安定な注射用製剤
EP2213743A1 (en) * 2000-04-12 2010-08-04 Human Genome Sciences, Inc. Albumin fusion proteins
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
BR0111196A (pt) 2000-05-26 2004-04-06 Idenix Cayman Ltd Composições e uso das mesmas para tratamento de flavivìrus e pestivìrus
CN1516599A (zh) * 2000-10-18 2004-07-28 ���鹫˾ 病毒唑-聚乙二醇化干扰素α联合治疗慢性传染性丙型肝炎的方法
AU2002365436B8 (en) * 2001-11-09 2008-04-03 Intarcia Therapeutics, Inc. Method for treating diseases with omega interferon
ES2500918T3 (es) 2001-12-21 2014-10-01 Human Genome Sciences, Inc. Proteínas de fusión de albúmina e interferón beta
US7608600B2 (en) 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
EP1536804A4 (en) 2002-06-28 2007-10-31 Idenix Cayman Ltd 2'-C-METHYL-3'-O-L-VALINESTER-RIBOFURANOSYLCYTIDINE FOR THE TREATMENT OF FLAVIVIRIDAE INFECTIONS
KR20050048544A (ko) 2002-06-28 2005-05-24 이데닉스 (케이만) 리미티드 플라비비리다에 감염 치료용의 변형된 2' 및3'-뉴클레오사이드 프로드럭
CA2506129C (en) 2002-11-15 2015-02-17 Idenix (Cayman) Limited 2'-branched nucleosides and flaviviridae mutation
CA2529311A1 (en) * 2003-03-28 2004-10-07 Pharmasset, Inc. Compounds for the treatment of flaviviridae infections
JP2006528679A (ja) * 2003-04-01 2006-12-21 インターミューン インコーポレイテッド コロナウイルス感染症及びサースを治療するための組成物及び方法
JP2006523655A (ja) * 2003-04-17 2006-10-19 アレス トレーディング ソシエテ アノニム 重症急性呼吸器症候群（ｓａｒｓ）におけるインターフェロンベータ
EP4032897A1 (en) 2003-05-30 2022-07-27 Gilead Pharmasset LLC Modified fluorinated nucleoside analogues
JP2006527268A (ja) * 2003-06-09 2006-11-30 ゲノム インスティチュート オブ シンガポール 臨床的に認められた抗ウイルス剤を用いるｓａｒｓコロナウイルス感染の阻害
US20070202078A1 (en) * 2003-08-13 2007-08-30 Smith Howard J Method Of Treating Viral Infections
AR045870A1 (es) * 2003-10-11 2005-11-16 Vertex Pharma Terapia de combinacion para la infeccion de virus de hepatitis c
US8492539B2 (en) 2004-09-14 2013-07-23 Gilead Pharmasset Llc Preparation of 2′-fluoro-2′-alkyl-substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives
TW201424733A (zh) * 2004-10-29 2014-07-01 Vertex Pharma 劑量型式
CN101448497B (zh) * 2006-01-09 2013-07-10 罗马克实验室有限公司 包含硝唑尼特、替唑尼特、或其混合物的组合物在制备治疗丙型肝炎药物中的应用
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
KR20100056479A (ko) 2007-07-25 2010-05-27 바이오렉스 쎄라퓨틱스, 인코포레이티드 제어 방출 인터페론 약물 제품 및 이를 사용한 ｈｃｖ 감염의 치료
TW200946541A (en) 2008-03-27 2009-11-16 Idenix Pharmaceuticals Inc Solid forms of an anti-HIV phosphoindole compound
EP2376088B1 (en) 2008-12-23 2017-02-22 Gilead Pharmasset LLC 6-O-Substituted-2-amino-purine nucleoside phosphoramidates
CN102753563A (zh) 2008-12-23 2012-10-24 吉利德制药有限责任公司 核苷类似物
CN102325783A (zh) 2008-12-23 2012-01-18 法莫赛特股份有限公司 嘌呤核苷的合成
ES2537785T3 (es) 2009-05-08 2015-06-12 Sciclone Pharmaceuticals, Inc. Péptidos de alfa timosina como potenciadores de vacunas
TWI583692B (zh) 2009-05-20 2017-05-21 基利法瑪席特有限責任公司 核苷磷醯胺
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
PT3290428T (pt) 2010-03-31 2021-12-27 Gilead Pharmasset Llc Comprimido compreendendo 2-(((s)-(((2r,3r,4r,5r)-5-(2,4-dioxo-3,4-dihidropirimidin-1-(2h)-il)¿4¿fluoro¿3¿hidroxi¿4¿metiltetrahidrofuran¿2¿il)metoxi) (fenoxi)fosforil)amino)propanoato de (s)- isopropil cristalino
EP2624840A1 (en) * 2010-10-05 2013-08-14 Novartis AG New treatments of hepatitis c virus infection
AU2011336632B2 (en) 2010-11-30 2015-09-03 Gilead Pharmasset Llc Compounds
KR102198749B1 (ko) * 2011-03-02 2021-01-06 제롬 쉔타그 단독으로 또는 c형 간염 바이러스 감염과 결합되는 간 지방증의 치료를 위한 조성물, 방법 및 진단
CN106166160A (zh) 2011-09-16 2016-11-30 吉利德制药有限责任公司 用于治疗hcv的组合物
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
KR20140119012A (ko) 2013-01-31 2014-10-08 길리어드 파마셋 엘엘씨 두 항바이러스 화합물의 병용 제형물
SI3038601T1 (sl) 2013-08-27 2020-07-31 Gilead Pharmasset Llc Formulacija kombinacije dveh protivirusnih spojin

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4211771A (en) 1971-06-01 1980-07-08 Robins Ronald K Treatment of human viral diseases with 1-B-D-ribofuranosyl-1,2,4-triazole-3-carboxamide
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
US4492537A (en) 1982-12-10 1985-01-08 Awerkamp John B Fluid-operated oil or water well pump
US4917888A (en) 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
JP2514950B2 (ja) 1986-03-10 1996-07-10 エフ・ホフマン―ラ ロシユ アーゲー 化学修飾蛋白質，その製造法および中間体
US5595732A (en) 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5382657A (en) 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
ATE214940T1 (de) 1993-11-10 2002-04-15 Enzon Inc Verbesserte interferon-polymerkonjugate
US5766582A (en) 1994-10-11 1998-06-16 Schering Corporation Stable, aqueous alfa interferon solution formulations
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
TW426523B (en) 1995-04-06 2001-03-21 Hoffmann La Roche Interferon solution
US6387365B1 (en) * 1995-05-19 2002-05-14 Schering Corporation Combination therapy for chronic hepatitis C infection
US5908621A (en) * 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
ATE262920T1 (de) * 1995-11-02 2004-04-15 Schering Corp Kontinuierliche, niedrigdosierte zytokine- infusionstherapie
TW517067B (en) 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
CA2298543A1 (en) 1997-08-13 1999-02-25 James Barry Loading and release of water-insoluble drugs
ATE206618T1 (de) * 1997-09-21 2001-10-15 Schering Corp Kombinationstherapie zur entfernung von nachweisbarer hcv-rns in patienten mit chronischer hepatitis c-infektion

Also Published As

Publication number Publication date
CZ20004177A3 (cs) 2001-04-11
DE69901321D1 (de) 2002-05-29
IL207259A (en) 2016-08-31
HU230432B1 (hu) 2016-06-28
IL139220A (en) 2013-02-28
EP0956861B1 (en) 2002-04-24
DK0956861T3 (da) 2002-07-01
KR20010043624A (ko) 2001-05-25
HUP0103423A3 (en) 2003-11-28
WO1999059621A1 (en) 1999-11-25
ATE216591T1 (de) 2002-05-15
BR9910505A (pt) 2001-01-02
AU2005220271B8 (en) 2010-11-18
MY129244A (en) 2007-03-30
JP2002515453A (ja) 2002-05-28
NO330715B1 (no) 2011-06-20
AU2005220271B2 (en) 2005-11-03
EP0956861A1 (en) 1999-11-17
AU2005220271A1 (en) 2005-11-03
IL207259A0 (en) 2010-12-30
EP1213029A1 (en) 2002-06-12
CN1230198C (zh) 2005-12-07
AU3860099A (en) 1999-12-06
JP5281726B2 (ja) 2013-09-04
CA2331823A1 (en) 1999-11-25
CZ300540B6 (cs) 2009-06-10
IL139220A0 (en) 2001-11-25
HK1021131A1 (en) 2000-06-02
AU2005220271B9 (en) 2010-12-09
ES2172288T3 (es) 2002-09-16
NZ507621A (en) 2002-11-26
NO20005755L (no) 2001-01-12
CN1309568A (zh) 2001-08-22
HUP0103423A2 (hu) 2002-01-28
AR019551A1 (es) 2002-02-27
EP2305287A1 (en) 2011-04-06
KR100694345B1 (ko) 2007-03-12
NO20005755D0 (no) 2000-11-14
SK17102000A3 (sk) 2001-05-10
AU766597B2 (en) 2003-10-16
DE69901321T2 (de) 2002-12-12
TWI277424B (en) 2007-04-01
SK288038B6 (en) 2013-01-02
JP2011173898A (ja) 2011-09-08

Similar Documents

Publication Publication Date Title
PT956861E (pt) Terapia combinada compreendendo ribavirina e interferao alfa em doentes sem tratamento antiviral anterior tendo infeccao cronica pelo virus da hepatite c
CA2334267A1 (en) Use of peg-ifn-alpha and ribavirin for the treatment of chronic hepatitis c
DK1136075T3 (da) Kombinationsterapi til udryddelse aff detekterbart HCV-RNA i patienter med kronisk hepatitis C infektion
NO20025627D0 (no) Fremgangsmåter og sammensetninger for å behandle hepatitt C virus
CO5241354A1 (es) Terapia de combinacio para vhc
TR200101085T2 (tr) Kronik hepatit C enfeksiyonlu hastalarda algılanabilir HCV-RNA'nın yok edilmesi için birleşik ribavirin-interferon alfa tedavisi
BR9913951A (pt) Tratamento de infecção de hepatite b com timosina alfa 1 em combinação com lamivudina e flamciclovir
DK1311279T3 (da) Behandling af hepatitis C med thymosin, interferon og ribavirin
SI1311279T1 (sl) Zdravljenje hepatitisa c s timozinom, interferonom in ribavirinom
DK1311286T3 (da) Behandling af hepatitis C med thymosin og pegyleret interferon